EverSea Medicines Acquires Hasten Biopharmaceuticals (Asia) Limited Shares

EverSea Medicines, a subsidiary of Everest Medicines, has signed an agreement to acquire the equity interest in Hasten Biopharmaceuticals (Asia) Limited. The acquisition positions Everest Medicines to expand its presence in the Asia Pacific region by integrating the 14 branded chronic disease products from Hasten Biopharmaceuticals. The deal involves an aggregate consideration of USD250 million, with installments spread across several years. The acquisition includes specific rights and commercial assets held by Hasten Biopharmaceuticals, contributing to Everest Medicines’ regional growth strategy. Hasten Biopharmaceuticals specializes in chronic disease products, focusing on cardiovascular and metabolic segments in the Asia Pacific market. Everest Medicines…